Dyax Corp. (NASDAQ: DYAX) today announced financial results for the first quarter ended March 31, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers – the hereditary angioedema (HAE) business, including KALBITOR® (ecallantide) and DX-2930, and the Licensing and Funded Research Portfolio (LFRP).
Help employers find you! Check out all the jobs and post your resume.
